Trial Profile
Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Rolapitant (Primary) ; Dexamethasone; Doxorubicin; Fosaprepitant; Ifosfamide; Mesna; Ondansetron; Vincristine
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 14 Jul 2020 Status changed from completed to discontinued.
- 11 Jul 2020 Status changed from recruiting to completed.
- 09 Aug 2019 Planned End Date changed from 1 Oct 2020 to 31 Dec 2020.